The report discusses Medicaid coverage of FDA-approved medications for treatment of alcohol and opioid use disorders, limitations on coverage (such as prior authorization requirements), background on federal laws and policies and innovative practices and policies at the state level.
The Statewide Drug Policy Advisory Council presents its 2018 Annual Report which is a compilation of information from the members of the Council.
These NIATx fact sheets provide easy access to information on using FDA-approved medications as part of a comprehensive treatment plan for substance use disorders.
This brief describes four key challenges related to the use of medication-assisted treatment (MAT) in child welfare contexts for parents with opioid use disorder. (DHHS, 11/18)
An annual data brief (No. 328, 11/18) published by the CDC’s National Center for Health Statistics presents U.S. mortality data on death rates showing that life expectancy at birth decreased in 2017, largely because of increases in mortality from unintentional injuries, suicide, diabetes, and influenza and pneumonia. (12/4/18)
New collateral print material (below) is incorporated into the Florida Department of Children and Families Overdose Prevention Program educating the public about helping people at risk of experiencing an overdose.
Print #1 - Print #2 - Print #3
The Drug Enforcement Administration has recently published the results of the 2018 National Drug Threat Assessment, which outlines the threats posed to the United States by domestic and international drug trafficking and the abuse of illicit drugs.
SAMHSA has released 3 new tobacco cessation publications for providers and clients, geared specifically towards substance use disorder treatment settings.
At the Medicare Part D Conference, CMS updated participants regarding their Opioid Overutlilization Strategies in compliance with the Comprehensive Addiction and Recovery Act.
The Medicare Part D Opioid Prescribing Mapping Tool is an online interactive mapping tool that presents geographic comparisons of the opioid prescribing rate at the state, county, and ZIP code levels. The mapping tool presents data for 2016 as well as changes in rates from 2013 to 2016.
Shifts in language, prevalence data, and a digital postcard are some of the resources available through this new report, published through the U.S. Department of Health and Human Services. (9/18)
The 2018 Florida Youth Substance Abuse Survey was just released. In its 19th year, four state agencies – the Departments of Children and Families, Health, Education, and Juvenile Justice - collaborate to administer and provide information to help reduce and prevent the use of alcohol, tobacco and other drugs by school-aged youth. The report includes drug use prevalence rates, valuable prevention planning data and an analysis of risk and protective factors among students.
The Philadelphia Department of Behavioral Health and Intellectual disAbility Services's toolkit is designed to support behavioral health treatment agencies with the process of integrating peer providers into their service settings.
Synthetic cannabinoids are part of the illicit drug category called novel psychoactive substances. NPS are often unregulated and are designed to enter a gray area of the market. The Organized Crime Drug Enforcement Task Force in the Department of Justice, the Centers for Disease Control and Prevention, and NMS Labs of Philadelphia are analyzing, identifying, and characterizing drug samples intercepted upon entry into the United States. (FADAA Substance Abuse Trends Alert, July 2018)
Cigarette Alternatives and Florida’s Youth examines current studies related to tobacco use among Florida’s youth. Statistics related to alternate methods of consuming nicotine are explored and education resources are included. (FADAA Substance Abuse Trends Alert, July 2018)
This report provides a brief statewide and regional update of the substance abuse issues and trends in Florida most recently addressed in the 2018 Annual Report, Patterns and Trends of Substance Use Within and Across the Regions of Florida. This update is based on information from multiple new sources available as of May 2018. (June 2018)
Published by the Office of Mental Health and Suicide Prevention, this report expands on prior analysis of Veteran suicide and examines mortality records, assessing characteristics and rates of suicide. (June 2018)
There are emerging concerns related to the illicit use of stimulants, including data about the growing harm from the abuse of stimulant drugs in Florida and the nation (FADAA Substance Abuse Trends Alert, June 2018)
Updated in June, the SAMHSA Opioid Overdose Prevention Toolkit offers information and facts from literature and links to resources to prevent opioid-related overdoses and deaths. Because interdisciplinary collaboration is critical to success, SAMHSA offers the Toolkit as an educational resource for community members, first responders, prescribers, patients, and families.
Education plays a critical role in preventing substance abuse. Drugs of Abuse, A DEA Resource Guide, is designed to be a reliable resource on the most commonly abused and misused drugs in the United States. This comprehensive guide provides important information about the harms and consequences of drug use by describing a drug’s effects on the body and mind, overdose potential, origin, legal status, and other key facts. (May 2018)
Popular media often portrays illicit drug use as a problem disproportionately affecting metropolitan communities. However, research and data trends do not support that portrayal. While rural and non-rural communities may face unique challenges when it comes to illicit drug use, data indicates that opioid use prevalence rates are comparable.(FADAA Substance Abuse Trends Alert, April 18)
This report provides a statewide and regional overview of substance abuse issues and trends in Florida using information from multiple sources available as of December 2017. It includes information about the progress of the opioid epidemic in Florida, describes historic declines in alcohol use, binge drinking and cigarette smoking among Florida’s middle and high school students and trends in the use of cocaine and Novel Psychoactive Substances. (May 2018)
SAMHSA's new Resource Center contains a collection of science-based resources for a broad range of audiences, including Treatment Improvement Protocols, toolkits, resource guides, and clinical practice guidelines. Recognizing the enormity of the opioid epidemic, the Resource Center includes an opioid-specific resources section.
Sterling Gildersleeve, Director, presents some important steps Phoenix Recovery Support Services in Chicago, Illinois is taking to prevent opioid overdose among its residents.
Heartland Center for Systems Change Senior Director, Valery Shuman, underscores the importance of examining our misconceptions about people with substance use disorders.
The Chicago Recovery Alliance’s Director, Dan Bigg, explores the role of harm reduction in helping people with substance use disorders stay healthy.
Dr. Alexander Walley highlights the importance of working with active drug users to develop a concrete and realistic plan for how to prevent opioid overdose.
Recent International Actions to Control Deadly Fentanyl Analogs (FADAA Substance Abuse Trends Alert, 1/18)
International cooperation has led to new approaches designed to staunch the flow of fentanyl analogs into the United States.
Opioids and Cocaine: Rapidly Evolving Epidemics in Florida (FADAA Substance Abuse Trends Alert, 12/17)
This Clinical Guide provides comprehensive, national guidance for optimal management of pregnant and parenting women with opioid use disorder and their infants.
Developed by the Yale Program for Recovery and Community Health, this kit helps clients prepare for their first recovery planning meeting and was shared by Dr. Tondora as part of her 1/26/18 Strengths-Based Assessments and Person-Centered Treatment Planning.
SAMHSA has just published The Rx Pain Medications, a series of 13 fact sheets designed to increase awareness of the risks associated with prescription opioid use and misuse, as well as to educate patients who are prescribed opioids for pain about the risks and to provide resources on methods for alternative pain management.
This TIP reviews the use of the three FDA-approved medications used to treat opioid use disorder —methadone, naltrexone, and buprenorphine.
The Florida Department of Health’s factfinding workgroup met to consider strategies health care boards might employ to reduce opioid deaths in Florida.
Hospital stays involving hepatitis C increased 67 percent among Baby Boomer patients more than any other age group, according to a new AHRQ brief. Hospital stays involving hepatitis C nearly tripled likely due to increased needle use associated with the nation's opioid epidemic. Access the brief and visit Webinars to see our latest training on Infectious Disease Control for Persons Who Inject Drugs with Dr. Cook.
More than 1.6 Million Americans Could Die from Drugs, Alcohol and Suicide During Next Decade – A 60 Percent Increase from Previous 10 Years – according to a new report.
This report illustrates how improving community conditions can reduce the incidence and intensity of mental health challenges, and help activate resilience.
The Medical Examiners Commission recently produced their annual report that identifies drugs found in deceased persons investigated by Florida Medical Examiners. The data distinguishes between drugs indicated as the cause of death and other drugs that were present in the body at the time of death. Data was collected on Opioids, Benzodiazepines, and other drug categories.
The final report of the President’s Commission, published 11/2017.
This data visualization presents provisional counts for drug overdose deaths based on a current flow of mortality data in the National Vital Statistics System.
A collaborative effort between government entities, the 2017 Florida Youth Substance Abuse Survey was just released and assesses risk and protective factors among students. (8/20/18)
This publication provides guidance to clinicians who treat women that are pregnant or of childbearing age with substance use problems. Developed by the University of South Florida, Florida Medicaid Drug Therapy Management Program, and sponsored by the Florida Agency for Health Care Administration, the recommendations also address use of long-acting contraceptives in women of childbearing age
The drug-by-drug review of trends, progress, and challenges addresses: underage drinking; nicotine and E-cigarettes; vaping; marijuana; novel psychoactive substances such as synthetic cannabinoids, synthetic cathinones, tryptamines, and piperazines; cocaine; methamphetamine; heroin; non-medical misuse and abuse of medications such as prescription opioids, benzodiazepines, stimulants, and over the counter (OTC) medications. (June 2017)
This drug-by-drug review of trends, progress, and challenges addresses the astonishing proliferation of substance abuse among Florida youth and adults. (December 2016)